what happens around us is here

Drug Information Update

FDA/CDER/Division of Drug Information (DDI)

The Division of Drug Information (DDI) is CDER’s focal point for public inquiries. We serve the public by providing information on human drug products and drug product regulation byFDA.

The U.S. Food and Drug Administration today announced, in accordance with longstanding U.S. obligations under the Montreal Protocol on Substances that Deplete the Ozone Layer, seven metered-dose inhalers (MDI) used to treat asthma and chronic obstructive pulmonary disease (COPD) will be gradually removed from the U.S. marketplace. These inhalers contain ozone-depleting chlorofluorocarbons (CFCs), which are propellants that move medication out of the inhaler and into the lungs of patients. Alternative medications that do not contain CFCs are available.

The seven CFC inhalers are listed here by their brand names. The generic names for the medicines appear in parentheses:

  • Tilade Inhaler (nedocromil)
  • Alupent Inhalation Aerosol (metaproterenol)
  • Azmacort Inhalation Aerosol (triamcinolone)
  • Intal Inhaler (cromolyn)
  • Aerobid Inhaler System (flunisolide)
  • Combivent Inhalation Aerosol (albuterol and ipratropium in combination)
  • Maxair Autohaler (pirbuterol)


April 14, 2010 - Posted by | 1

1 Comment »

  1. t’s probably why; I’ve been perscribed Albuteral Sulfate Inhaler_Ventolin…

    Comment by mjraff | April 14, 2010 | Reply

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: